Can the Platelet Function Analyzer (PFA®)-100 test substitute for the template bleeding time in routine clinical practice?

Abstract

The bleeding time (BT) is widely used in clinical medicine as a screening test of platelet function, although its deficiencies in such a role are well recognized. The Platelet Function Analyzer (PFA)®-100 measures the ability of platelets activated in a high-shear environment to occlude an aperture in a membrane treated with collagen and epinephrine (CEPI) or collagen and ADP (CADP). The time taken for flow across the membrane to stop (closure time) is recorded. This study compared the PFA®-100 with the BT as a screening test of platelet dysfunction in 113 hospital inpatients. The PFA®-100 test was performed initially using the CEPI cartridge; CADP tests were performed on those with abnormal (> 163s) CEPI closure times. Whole blood platelet aggregation studies and chart review were performed on patients in whom the BT and PFA®-100 results did not agree. Abnormal bleeding times and PFA®-100 results were obtained in 20.4% and 35.4% of patients, respectively. The results of BT and PFA®-100 agreed in 74.3% of patients. Of the 29 patients in whom the BT and PFA®-100 results were discordant, whole blood platelet aggregation studies supported the PFA®-100 result in 25 (86.2%). The PFA®-100 was more sensitive to aspirin-induced platelet dysfunction and was more rapidly and cheaply performed than the BT. Since the PFA®-100 test reflects platelet function better than the BT, we conclude that this test could replace the BT as a first-line screening test for platelet dysfunction in clinical practice.